Female Sexual Dysfunction - 2005 physician survey

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-06-06

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.


Scope

  • Review of the disease definition, classification and key patient segmentation for female sexual dysfunction
  • Assessment of the current unmet needs in the treatment of female sexual dysfunction
  • Exploration of the screening, presentation and referral patterns within the female sexual dysfunction population in the 5EU and US
  • Prescription and treatment trends among important subcategories of female sexual dysfunction, such as hypoactive sexual desire disorder (HSDD)


    • Report Highlights
    Testosterone therapies are already widely used among women with hypoactive sexual desire disorder and female sexual arousal disorder. There is a significant market for a formally approved testosterone product for women, with 85% of prescribers willing to switch existing testosterone users onto an approved product.

    There is a distinct need for more specialized services in support of those with sexual functioning problems. There is no clear referral pathway for primary care physicians and no specialist service for patients to present directly to. This causes a barrier to presentation, diagnosis and treatment.

    The identification and classification of FSD is biased by physician's perception. A woman presenting with sexual difficulties could receive a variety of diagnoses or even no diagnosis at all. There is a need not only for a more holistic approach to sexual dysfunction, but also for validated and consistent tools to assess and diagnose patients.


    Reasons to Purchase

  • Understand key opinion leaders views on topical issues in the female sexual dysfunction market
  • View quantified, pictorial treatment pathways of female sexual dysfunction patients in the UK, US and Spain
  • Examine treatment trends for female sexual dysfunction subtypes, hypoactive sexual desire disorder and female sexual arousal disorder

    • Table of Contents

    Other users found this report page using the following search terms: fsd fad sexual dysfunction sexual dysfunction female treatment hsdd survey disorder women physician hypoactive

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.